Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
- Conditions
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Centre of Postgraduate Medical Education
- Target Recruit Count
- 60
- Registration Number
- NCT02085824
- Locations
- ๐ต๐ฑ
Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education, Otwock, Woj. Mazowieckie, Poland
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2199
- Registration Number
- NCT02072434
- Locations
- ๐ช๐ธ
First site in, Madrid, Spain
๐ช๐ธThird site in, Madrid, Spain
๐ฉ๐ชBad Friedrichshall, Heilbronn, Germany
Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- MemorialCare Health System
- Target Recruit Count
- 90
- Registration Number
- NCT02070237
- Locations
- ๐บ๐ธ
Long Beach Memorial Care Center for Women at Miller Children's Hospital Long Beach and Long Beach Memorial Hospital, Long Beach, California, United States
Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2013-10-28
- Lead Sponsor
- Dr. Sidney Ben Chetrit
- Target Recruit Count
- 26
- Registration Number
- NCT01970280
- Locations
- ๐ฎ๐ฑ
Department of Nephrology and Hypertension, Meir Medical Center, Kfar Sava, Israel
๐ฎ๐ฑHelsinki committee, Kfar Sava, Israel
Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Pejman Ghanouni
- Target Recruit Count
- 5
- Registration Number
- NCT01965002
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 94
- Registration Number
- NCT01911624
- Locations
- ๐ง๐ช
KUleuven/UZ Gasthuisberg, Leuven, Belgium
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
- Conditions
- Interventions
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Berlin-Chemie AG Menarini Group
- Target Recruit Count
- 312
- Registration Number
- NCT01880216
- Locations
- ๐ท๐บ
St. Petersburg State Public Health Institution "City Multi-field Hospital #2", Saint-Petersburg, Russian Federation
๐ท๐บState Budget Public Health Institution of Yaroslavl region "Clinical hospital #10", Municipal Clinical Public Health Institution " Medical Unit of Novo-Yaroslavl Petroleum Refinery", Yaroslavl, Russian Federation
๐ท๐บState Budget Public Health Institution of Yaroslavl Region "Regional Clinical Hospital", Yaroslavl, Russian Federation
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 279
- Registration Number
- NCT01839487
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
๐บ๐ธLahey Clinic, Burlington, Massachusetts, United States
Enoxaparin Dosing in Obesity
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 62
- Registration Number
- NCT01798550
- Locations
- ๐บ๐ธ
Grady Memorial Hospital, Atlanta, Georgia, United States
Enoxaparin Versus Aspirin in Patients With Cancer and Stroke
- Conditions
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01763606
- Locations
- ๐บ๐ธ
New York Presbyterian Hospital, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering West Harrison, Harrison, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.